Insights & Discussion
A dietary supplement Avocado/Soybean Unsaponifiables aids in treating Osteoarthritis by preventing cartilage degradation and promoting cartilage repair, thereby reducing pain and enhancing joint functionality.
Avocado/Soybean Unsaponifiables was studied for its effects on Osteoarthritis. The methodology highlighted its functions, which include inhibiting the release and activity of molecules and pathways that are implicated in OA, as well as those that prevent cartilage degradation. These functions are principally through the prohibition of matrix metalloproteinases and the increase of tissue inhibitors of the catabolic enzymes in question. Additionally, ASU was found to inhibit fibrinolysis by stimulating the expression of plasminogen activator inhibitor. Moreover, its anabolic properties were credited with promoting cartilage repair by stimulating collagen and aggrecan synthesis while inhibiting inflammatory cytokines.
ASU's chondroprotective effects were noted as well; these effects are brought about by correcting growth factor abnormalities, and by simultaneously increasing Transforming Growth Factor-Beta in synovial fluid while decreasing vascular endothelial growth factor. Additionally, it was observed to inhibit cholesterol absorption and biosynthesis, which further contribute to its beneficial role by moderating reactive oxygen species pathology in chondrocytes.
Results indicated that the dietary supplement has significant therapeutic value for those suffering from Osteoarthritis. It reduces pain and stiffness while improving joint function, resulting in less dependency on painkillers. It was found that ASU's preventative measures towards cartilage degradation and its promotion of cartilage repair play essential roles in its efficiency as a treatment for OA.
Discover Related Insights
PIASCLEDINE-ExpASU®, a type of avocado/soybean unsaponifiable product, displays superior pharmacological activity due to its unique composition, including a high inhibitory effect on pro-inflammatory factors.
2022 Frontiers in Pharmacology Composition Analysis and Pharmacological Activity of Avocado/Soybean Unsaponifiable Products Used in the Treatment of Osteoarthritis Lambert C, Bellemère G, Boyer G, Ponelle F, Bauer T, Legeny MC, et al.
Experimental Study Avocado-Soybean Unsaponifiables Osteoarthritis
The study began with the characterisation of the lipid content of seven different avocado/soybean unsaponifiable (ASU) products through gas chromatography analysis performed on a VARIAN 3400 chromatograph. In parallel, the effects of these products were tested on human osteoarthritis chondrocytes (cartilage cells) cultured in alginate beads. The researchers focused on the effects of these ASU products on aggrecan, key interleukins, and matrix metalloproteases.
In terms of results, PIASCLEDINE-ExpASU® stood out due to a specific profile involving unique chromatographic peaks and the presence of specific compounds like alkyl furan fraction, alkyl triols, and squalene. Remarkably, this product showed heightened efficacy in inhibiting production of nitric oxide, interleukins, and catabolic factors. Meanwhile, excepting two products, the remaining ASUs showed varied capacity in increasing aggrecan production, a positive factor in the context of osteoarthritis treatment.
Avocado/soy unsaponifiables effectively treat osteoarthritis by controlling the balance between oxidant and antioxidant molecular markers.
2021 Journal of Complementary and Integrative Medicine Avocado/soy unsaponifiables can redress the balance between serum antioxidant and oxidant levels in patients with osteoarthritis: a double-blind, randomized, placebo-controlled, cross-over study Jangravi Z, Basereh S, Zaree Mahmoudabadi A, Saberi M, Alishiri GH, Korani M
Randomised Controlled Trial Avocado Avocado Unsaponifiable Osteoarthritis
The methodology used in this study was a double-blind, randomized, placebo-controlled, cross-over trial. Forty osteoarthritis patients were classified into two groups: one received avocado/soy unsaponifiables (ASU) for three months followed by three months of placebo, and the other group received a placebo first for three months followed by three months of ASU. The patients' oxidant status was evaluated by measuring their serum malonldialdehyde (MDA). Other measures such as total antioxidant capacity, reduced glutathione, and antioxidant enzymes like superoxide dismutase and catalase were also assessed.
After three months of treatment, all patients who were given avocado/soy unsaponifiables exhibited a significant decrease in their serum MDA levels, indicating lower oxidative stress. In comparison, these levels were higher at baseline and after placebo treatment. Furthermore, the treatment with avocado/soy unsaponifiables resulted in positive changes in the patients' antioxidant levels. Analysis also showed that the effect of avocado/soy unsaponifiables was consistent, regardless of the sequence in which the medication was received. These findings demonstrate that avocado/soy unsaponifiables can contribute effectively to the treatment of osteoarthritis by regulating the balance between oxidant and antioxidant molecular markers.
Avocado and soybean unsaponifiables may effectively reduce inflammation and symptoms related to osteoarthritis, autoimmune diseases, and menopause.
2020 Biomolecules Avocado–Soybean Unsaponifiables: A Panoply of Potentialities to Be Exploited Salehi B, Rescigno A, Dettori T, Calina D, Docea AO, Singh L, et al.
Review Article Autoimmune Disease Avocado-Soybean Unsaponifiables Menopause
The research involves summarizing various studies on the biological effects of the avocado-soybean unsaponifiables (ASU), highlighting its potent anti-inflammatory properties. The extracted ASU are a combination of elements derived from the fruits and seeds of avocados and soybeans. To understand its impact, the researchers categorized the applications of ASU in treating different conditions such as osteoarthritic pain, hip and knee osteoarthritis, autoimmune diseases, and menopause-related symptoms amongst postmenopausal women.
The discussion revealed significant links between avocado and soybean unsaponifiables and symptom improvement in areas of osteoarthritic pain, autoimmune conditions, and postmenopause. Particularly notable is the ASU mixture's potential role as an adjunct treatment, meaning it’s meant to supplement primary treatments for such conditions. Its benefits were not only limited to physical reduction of inflammation and associated pain, but also improved mood and quality of life for postmenopausal women by significantly reducing menopause-related symptoms. The study also delves into the safety, toxicological considerations, and regulatory practices related to the use of ASU.
Avocado-soybean unsaponifiables treatment is effective in reducing knee osteoarthritis symptoms without increasing adverse events, contrary to those with hip osteoarthritis.
2019 International Journal of Rheumatic Diseases Efficacy and safety of avocado‐soybean unsaponifiables for the treatment of hip and knee osteoarthritis: A systematic review and meta‐analysis of randomized placebo‐controlled trials Simental‐Mendía M, Sánchez‐García A, Acosta‐Olivo CA, Vilchez‐Cavazos F, Osuna‐Garate J, Peña‐Martínez VM, et al.
Systematic Review Avocado Avocado-Soybean Unsaponifiables Knee Osteoarthritis
To assess avocado-soybean unsaponifiables (ASU) effectiveness and safety, a systematic review and meta-analysis of randomized controlled trials involving patients with hip or knee osteoarthritis was conducted. Various scientific databases, including Medline, SCOPUS, Web of Science, and Google Scholar, were thoroughly searched for suitable trials. Selection criteria consisted of randomized placebo-controlled trials wherein the effect of orally administered ASU on knee or hip osteoarthritis symptoms were evaluated, primarily using the Lequesne index, visual analog scale, and joint space width.
The meta-analysis revealed a significant reduction in pain as assessed by the visual analog scale for those under Avocado-soybean unsaponifiables therapy, particularly for patients with knee osteoarthritis, indicated by a decrease in both the visual analogue scale and Lequesne index. However, no such significant effect was found for patients with hip osteoarthritis. In terms of safety, there were no significant differences in adverse events between patients receiving ASU and those given a placebo, confirming ASU's relative safety as a treatment option.